U-Neuron Biomedical

U-Neuron Biomedical ROA

The Return on Assets (ROA) of U-Neuron Biomedical (6973.TWO) as of Oct 27, 2026 is -7.08 %. In the previous year, Return on Assets (ROA) was -16.23 % — a change of -56.35% (higher).

ROA

-7.08 %

YoY

-56.35%

Last updated:

In 2024, U-Neuron Biomedical's return on assets (ROA) was -7.08 %, a -56.35% increase from the -16.23 % ROA in the previous year.

The U-Neuron Biomedical ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2021
-5.33 TWD
Jan 1, 2022
-23.17 TWD
Jan 1, 2023
-16.23 TWD
Jan 1, 2024
-7.08 TWD
The U-Neuron Biomedical ROA history
YEARROAYoY
-7.08 %-56.35%
-16.23 %-29.98%
-23.17 %+335.08%
-5.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc develops cosmetics, health care consumer products, and new drugs using allogeneic amniotic fluid stem cells and their derivatives. The company's new drug portfolio includes UA002 for erectile dysfunction and UB003 for dry eye, while its cosmetic line features masks, essences, and creams for anti-aging, repairing, and moisturizing. These products are primarily sold within Taiwan, targeting domestic consumers seeking medical beauty and health care solutions. The company leverages the regenerative properties of amniotic fluid stem cells to create applications in both therapeutic and cosmetic segments. The business model focuses on developing products around deer amniotic fluid stem cell derivatives for cosmetics, which form the core of its health care consumer product line. UA002 and UB003 represent the company's pharmaceutical offerings, addressing specific medical conditions with stem cell-based treatments. Domestic sales drive revenue, with no mention of international markets or additional distribution channels in the provided description. U-Neuron Biomedical Inc's revenue streams come from the domestic sale of its cosmetic products and pharmaceuticals. The company's product segments are clearly divided between new drug development and cosmetic/health care consumer products, with each segment utilizing stem cell technology in different applications. Sales are concentrated within Taiwan, where the company's products meet local demand for regenerative medicine and beauty solutions. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

ROA Details

Understanding U-Neuron Biomedical's Return on Assets (ROA)

U-Neuron Biomedical's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing U-Neuron Biomedical's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider U-Neuron Biomedical's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in U-Neuron Biomedical’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about U-Neuron Biomedical stock

Return on Assets (ROA) of U-Neuron Biomedical is -7.08 % in 2024.

Return on Assets (ROA) of U-Neuron Biomedical changed from -16.23 % to -7.08 %, representing a -56.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s U-Neuron Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — U-Neuron Biomedical

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — U-Neuron Biomedical